The move has been triggered by the shortage of drugs — most of them supplied by Indian generic drug companies — that the US faces during the Covid-19 pandemic. The Indian Pharmaceutical Alliance has asked the FDA last month to find a solution for inspecting the manufacturing plants of its members.from Industry-Economic Times
Read The Rest:economictimes...
